Table 4

Clinical response of 2% ganciclovir eye drop compared with baseline 1 week–6 months

Baseline1 week4 weeks2 months3 months4 months5 months6 months
Median
(min–max)
Median
(min–max)
Median
(min–max)
Median
(min–max)
Median
(min–max)
Median
(min–max)
Median
(min–max)
Median
(min–max)
Visual acuity0.2 (0–1.4)0.3 (0–1.4)0.5 (0–1.1)0.2 (0–1.3)0.4 (0–1.3)0.2 (0–1.1)0.2 (0–1.1)0.1 (0–1.1)
p = 0.031p = 0.095p = 0.078p = 0.065p= 0.065p= 0.020p= 0.011
Cell0.5 (0–4)0 (0–3)0 (0–1)0 (0–1)0 (0–0.5)0 (0–2)0 (0–1)0 (0–1)
p = 0.058p = 0.034p = 0.020p = 0.007p= 0.008p= 0.034p= 0.007
IOP28 (14–44)13 (12–20)15 (8–18)14 (8–16)11 (8–24)14 (8–16)14 (9–29)14 (7–18)
p = 0.013p = 0.012p = 0.006p = 0.11p= 0.005p= 0.012p= 0.003
Antiglaucoma drug3 (0–6)2 (0–5)2 (0–4)2 (0–4)1 (0–3)1 (0–4)1 (0–4)1 (0–3)
p = 0.024p = 0.010p = 0.011p = 0.007p= 0.011p= 0.011p= 0.007
Steroid4 (2–16)4 (0–16)2 (0–8)2 (0–4)2 (0–4)2 (0–8)2 (0–4)1 (0–4)
p = 0.176p = 0.017p = 0.018p = 0.11p= 0.005p= 0.007p= 0.005
KPs present 10 (90.9%)4 (36.36%)00001 (9.09%)0
p = 0.031NANANANAp= 0.004NA
  • Wilcoxon signed-rank test.

  • McNemar test.

  • Significant (p<0.05).

  • IOP, intraocular pressure; KPs, keratic precipitates.